JP2013518902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518902A5 JP2013518902A5 JP2012552115A JP2012552115A JP2013518902A5 JP 2013518902 A5 JP2013518902 A5 JP 2013518902A5 JP 2012552115 A JP2012552115 A JP 2012552115A JP 2012552115 A JP2012552115 A JP 2012552115A JP 2013518902 A5 JP2013518902 A5 JP 2013518902A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tetrahydro
- trifluoromethyl
- carbazol
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 206010006895 Cachexia Diseases 0.000 claims description 12
- 206010060800 Hot flush Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 238000002657 hormone replacement therapy Methods 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 208000033830 Hot Flashes Diseases 0.000 claims description 7
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010013883 Dwarfism Diseases 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010017076 Fracture Diseases 0.000 claims description 4
- 208000036119 Frailty Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010020112 Hirsutism Diseases 0.000 claims description 4
- 206010024264 Lethargy Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 206010049088 Osteopenia Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000027868 Paget disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 206010039792 Seborrhoea Diseases 0.000 claims description 4
- 208000020221 Short stature Diseases 0.000 claims description 4
- 208000013200 Stress disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 206010003549 asthenia Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000018631 connective tissue disease Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 208000027202 mammary Paget disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000028169 periodontal disease Diseases 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 229960003604 testosterone Drugs 0.000 claims description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000018035 Dental disease Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 3
- 208000016253 exhaustion Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 206010048828 underweight Diseases 0.000 claims description 3
- 230000001457 vasomotor Effects 0.000 claims description 3
- 230000004596 appetite loss Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 208000019017 loss of appetite Diseases 0.000 claims description 2
- 235000021266 loss of appetite Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 239000000460 chlorine Substances 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- -1 salt compound Chemical class 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- OZXBEIHRSWLQHT-GFCCVEGCSA-N (1r)-6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1[C@@](O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-GFCCVEGCSA-N 0.000 claims 1
- GLOACQUUNCBWQT-GFCCVEGCSA-N (1r)-6,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1[C@@](O)(C(F)(F)F)CCC2 GLOACQUUNCBWQT-GFCCVEGCSA-N 0.000 claims 1
- OZXBEIHRSWLQHT-LBPRGKRZSA-N (1s)-6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1[C@](O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-LBPRGKRZSA-N 0.000 claims 1
- UYVPMSMQBOHCIJ-UHFFFAOYSA-N 2,4-dichloro-6-(trifluoromethyl)-7,8,9,10-tetrahydro-5h-cyclohepta[b]indol-6-ol Chemical compound FC(F)(F)C1(O)CCCCC2=C1NC1=C(Cl)C=C(Cl)C=C21 UYVPMSMQBOHCIJ-UHFFFAOYSA-N 0.000 claims 1
- VJXGECHHOUASAO-UHFFFAOYSA-N 2-benzyl-5,6-dichloro-9h-carbazol-1-ol Chemical compound C1=CC(C2=C(Cl)C(Cl)=CC=C2N2)=C2C(O)=C1CC1=CC=CC=C1 VJXGECHHOUASAO-UHFFFAOYSA-N 0.000 claims 1
- KPGQCUGJRGDYSE-UHFFFAOYSA-N 2-benzyl-6,7-dichloro-9h-carbazol-1-ol Chemical compound C1=CC(C2=CC(Cl)=C(Cl)C=C2N2)=C2C(O)=C1CC1=CC=CC=C1 KPGQCUGJRGDYSE-UHFFFAOYSA-N 0.000 claims 1
- JWRPBUGOHRYASA-UHFFFAOYSA-N 2-bromo-6,7-dichloro-9h-carbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)=C(Br)C=C2 JWRPBUGOHRYASA-UHFFFAOYSA-N 0.000 claims 1
- QGJJANJFBJTWCT-UHFFFAOYSA-N 5,6,7-trichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 QGJJANJFBJTWCT-UHFFFAOYSA-N 0.000 claims 1
- ZMCLYZWHCWDGQL-UHFFFAOYSA-N 5,6,8-trichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 ZMCLYZWHCWDGQL-UHFFFAOYSA-N 0.000 claims 1
- BFVQEOVSAUKIEG-UHFFFAOYSA-N 5,6-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 BFVQEOVSAUKIEG-UHFFFAOYSA-N 0.000 claims 1
- UYSSSLCWLNMVTN-UHFFFAOYSA-N 5,6-dichloro-2-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)C(F)CC2 UYSSSLCWLNMVTN-UHFFFAOYSA-N 0.000 claims 1
- FFLPEQIVXOVSGF-UHFFFAOYSA-N 5,6-dichloro-2-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound C1=C(Cl)C(Cl)=C2C(CCC(C3(O)C(F)(F)F)C)=C3NC2=C1 FFLPEQIVXOVSGF-UHFFFAOYSA-N 0.000 claims 1
- YGHNPEADFBWJMM-UHFFFAOYSA-N 5,6-dichloro-9h-carbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)=CC=C2 YGHNPEADFBWJMM-UHFFFAOYSA-N 0.000 claims 1
- KKCKHZUAVYBTFB-UHFFFAOYSA-N 5,7-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CC2 KKCKHZUAVYBTFB-UHFFFAOYSA-N 0.000 claims 1
- MOOANAHHINSSPK-UHFFFAOYSA-N 5-chloro-6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(F)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 MOOANAHHINSSPK-UHFFFAOYSA-N 0.000 claims 1
- QBSXZCAAQUKLIN-UHFFFAOYSA-N 6,7-dichloro-1-(1,1,2,2,2-pentafluoroethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)C(F)(F)F)CCC2 QBSXZCAAQUKLIN-UHFFFAOYSA-N 0.000 claims 1
- OZXBEIHRSWLQHT-UHFFFAOYSA-N 6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-UHFFFAOYSA-N 0.000 claims 1
- FFQXLJXMHWLJMQ-UHFFFAOYSA-N 6,7-dichloro-1-methyl-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(C)(O)CCC2 FFQXLJXMHWLJMQ-UHFFFAOYSA-N 0.000 claims 1
- VSYXPEOPYUZLMW-UHFFFAOYSA-N 6,7-dichloro-2,2-difluoro-1-(trifluoromethyl)-4,9-dihydro-3h-carbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(C(F)(F)F)(O)C(F)(F)CC2 VSYXPEOPYUZLMW-UHFFFAOYSA-N 0.000 claims 1
- KGYITEFEOAWUCU-UHFFFAOYSA-N 6,7-dichloro-2-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)C(F)CC2 KGYITEFEOAWUCU-UHFFFAOYSA-N 0.000 claims 1
- BQKIMLLLBKPXOU-UHFFFAOYSA-N 6,7-dichloro-2-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound ClC1=C(Cl)C=C2C(CCC(C3(O)C(F)(F)F)C)=C3NC2=C1 BQKIMLLLBKPXOU-UHFFFAOYSA-N 0.000 claims 1
- KATFAQVKRVSADT-UHFFFAOYSA-N 6,7-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CC2 KATFAQVKRVSADT-UHFFFAOYSA-N 0.000 claims 1
- GLOACQUUNCBWQT-UHFFFAOYSA-N 6,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 GLOACQUUNCBWQT-UHFFFAOYSA-N 0.000 claims 1
- ZNQUFMFGFSMGLK-UHFFFAOYSA-N 6,8-dichloro-2,2-difluoro-1-(trifluoromethyl)-4,9-dihydro-3h-carbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(C(F)(F)F)(O)C(F)(F)CC2 ZNQUFMFGFSMGLK-UHFFFAOYSA-N 0.000 claims 1
- AQPPCKBTCIQHBJ-UHFFFAOYSA-N 6-chloro-8-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(F)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 AQPPCKBTCIQHBJ-UHFFFAOYSA-N 0.000 claims 1
- VAQQPYHQQCGPMC-UHFFFAOYSA-N 7,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C(Cl)=CC=C2C2=C1C(O)(C(F)(F)F)CCC2 VAQQPYHQQCGPMC-UHFFFAOYSA-N 0.000 claims 1
- HVDRWCKUQMRDGT-UHFFFAOYSA-N 7,8-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CC2 HVDRWCKUQMRDGT-UHFFFAOYSA-N 0.000 claims 1
- RKCMFKAWCUGATK-UHFFFAOYSA-N 7-chloro-6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(F)C=C2C2=C1C(O)(C(F)(F)F)CCC2 RKCMFKAWCUGATK-UHFFFAOYSA-N 0.000 claims 1
- FDRMTRSYPSJWQJ-UHFFFAOYSA-N 8-chloro-6-fluoro-1,2-bis(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(F)C=C2C2=C1C(O)(C(F)(F)F)C(C(F)(F)F)CC2 FDRMTRSYPSJWQJ-UHFFFAOYSA-N 0.000 claims 1
- UDUFALSRKCWTRJ-UHFFFAOYSA-N 8-hydroxy-1,8-bis(trifluoromethyl)-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=C(C(F)(F)F)C=C(C#N)C=C2C2=C1C(O)(C(F)(F)F)CCC2 UDUFALSRKCWTRJ-UHFFFAOYSA-N 0.000 claims 1
- DZMHVXDYRBLHFR-UHFFFAOYSA-N 8-hydroxy-8-(trifluoromethyl)-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=CC=C(C#N)C=C2C2=C1C(O)(C(F)(F)F)CCC2 DZMHVXDYRBLHFR-UHFFFAOYSA-N 0.000 claims 1
- IICQMRDIWOGNKM-UHFFFAOYSA-N 8-hydroxy-8-methyl-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=CC=C(C#N)C=C2C2=C1C(C)(O)CCC2 IICQMRDIWOGNKM-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 201000003073 testicular leukemia Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 1
- 0 CCC=C(C(CC(C)(C)*CC(C1[Rh])O)=C1N1)C1=CC=C Chemical compound CCC=C(C(CC(C)(C)*CC(C1[Rh])O)=C1N1)C1=CC=C 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30149210P | 2010-02-04 | 2010-02-04 | |
| US61/301,492 | 2010-02-04 | ||
| PCT/US2011/023768 WO2011097496A1 (en) | 2010-02-04 | 2011-02-04 | Selective androgen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035296A Division JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518902A JP2013518902A (ja) | 2013-05-23 |
| JP2013518902A5 true JP2013518902A5 (enExample) | 2015-05-28 |
| JP5964756B2 JP5964756B2 (ja) | 2016-08-03 |
Family
ID=44355809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552115A Expired - Fee Related JP5964756B2 (ja) | 2010-02-04 | 2011-02-04 | 選択的アンドロゲン受容体モジュレーター |
| JP2016035296A Pending JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035296A Pending JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8987319B2 (enExample) |
| EP (1) | EP2531029B1 (enExample) |
| JP (2) | JP5964756B2 (enExample) |
| AU (1) | AU2011212813B2 (enExample) |
| BR (1) | BR112012019551A2 (enExample) |
| CA (1) | CA2788907A1 (enExample) |
| MX (1) | MX338831B (enExample) |
| WO (1) | WO2011097496A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9193763B2 (en) | 2007-08-17 | 2015-11-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| DK2568806T3 (en) | 2010-05-12 | 2016-08-15 | Radius Health Inc | therapy Programs |
| WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
| CN103172643B (zh) * | 2011-12-26 | 2016-03-02 | 中国医学科学院药物研究所 | 黄皮咔唑生物碱及其制备方法和其药物组合物与用途 |
| EP3858341A1 (en) | 2012-11-15 | 2021-08-04 | Endocyte, Inc. | Psma ligand-containing conjugates for the treatment of prostate cancer |
| KR101947053B1 (ko) | 2013-10-18 | 2019-02-12 | 도이체스 크렙스포르슝스첸트룸 | 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제 |
| EP3533473A3 (en) | 2013-11-14 | 2019-12-18 | Endocyte, Inc. | Compounds for positron emission tomography |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| JP6757037B2 (ja) * | 2016-02-15 | 2020-09-16 | 学校法人近畿大学 | ストレス評価方法 |
| HRP20220619T1 (hr) | 2016-06-22 | 2023-02-03 | Ellipses Pharma Ltd | Postupci za liječenje ar+ raka dojke |
| EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| CN109239214B (zh) * | 2018-09-19 | 2020-01-31 | 珠海润都制药股份有限公司 | 一种沙库比曲钠中沙库比曲异构体检验方法 |
| MA54946A (fr) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals Inc | Procédés et composés |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| TW202334085A (zh) * | 2021-11-19 | 2023-09-01 | 大陸商杭州拿因生物科技有限責任公司 | 四氫咔唑類化合物、其藥物組成物及用途 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1547758A (en) | 1975-07-29 | 1979-06-27 | Shell Int Research | Herbicidal composition |
| JPH01261381A (ja) | 1988-04-12 | 1989-10-18 | Nippon Soda Co Ltd | オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤 |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| UA51652C2 (uk) | 1995-06-08 | 2002-12-16 | Новартіс Аг | Спосіб гідрування імінів |
| PT918774E (pt) | 1996-06-27 | 2002-05-31 | Ligand Pharm Inc | Compostos moduladores do receptor para androgenio e metodos |
| US20090264534A1 (en) | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
| FR2770842B1 (fr) | 1997-11-13 | 1999-12-17 | Oreal | Nouveaux composes derives de n-aryl 2-hydroxy alkylamides |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| JP2004509072A (ja) | 2000-06-28 | 2004-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法 |
| EP1401801B1 (en) | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| AU2003205461B2 (en) | 2002-02-15 | 2006-08-31 | Endorecherche, Inc. | Biphenyl Derivatives and their Use as Antiandrogenic Agents |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| US7297698B2 (en) | 2002-07-12 | 2007-11-20 | Astellas Pharma Inc. | N-phenyl-(2R,5S) dimethylpiperazine derivative |
| US7649001B2 (en) | 2002-08-12 | 2010-01-19 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| WO2004041277A1 (en) | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| UA79504C2 (en) | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
| EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
| EP1603858A2 (en) | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| JP2007505164A (ja) | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類 |
| WO2005000795A2 (en) | 2003-06-10 | 2005-01-06 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| US7446110B2 (en) | 2003-09-10 | 2008-11-04 | Merck & Co., Inc. | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| EP1687274A1 (en) | 2003-11-20 | 2006-08-09 | Warner-Lambert Company LLC | Androgen receptor modulators |
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| RU2397176C2 (ru) | 2004-01-07 | 2010-08-20 | Эндорешерш, Инк. | Стероидные фармацевтические продукты, направленные на спираль 12 |
| US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7514470B2 (en) | 2004-03-03 | 2009-04-07 | Smithkline Beecham Corporation | Aniline derivatives as selective androgen receptor modulators |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| JP2007223901A (ja) | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| US20080125399A1 (en) | 2004-04-08 | 2008-05-29 | Jiabing Wang | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators |
| TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
| EP2078712B1 (en) * | 2004-05-03 | 2015-06-10 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (sarms) |
| US7282507B2 (en) | 2004-05-03 | 2007-10-16 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
| EP1747193A1 (en) | 2004-05-11 | 2007-01-31 | Pfizer Products Incorporated | Benzonitrile derivatives to treat musculoskeletal frailty |
| ZA200610270B (en) | 2004-05-17 | 2008-06-25 | Acadia Pharm Inc | Androgen receptor modulators and method of treating disease using the same |
| AU2005247610A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Substituted thiazoleacetic as crth2 ligands |
| GEP20094851B (en) | 2004-06-07 | 2009-12-10 | The Univ Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| CN101056862B (zh) | 2004-09-10 | 2013-03-13 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂（sarms）的咪唑烷-2-酮衍生物 |
| WO2006034090A1 (en) | 2004-09-20 | 2006-03-30 | Janssen Pharmaceutica N.V. | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
| EP1805147B1 (en) | 2004-09-30 | 2014-08-13 | Janssen Pharmaceutica NV | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| EP1809275A1 (en) | 2004-10-13 | 2007-07-25 | Smithkline Beecham Corporation | Chemical compounds |
| AU2005310238A1 (en) | 2004-10-29 | 2006-06-08 | Merck Sharp & Dohme Corp. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| CN101103003A (zh) | 2004-11-16 | 2008-01-09 | 詹森药业有限公司 | 用作选择性雄激素受体调节剂(sarms)的新的杂环衍生物 |
| EP1817025A2 (en) * | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| JP5203712B2 (ja) | 2005-01-10 | 2013-06-05 | アカディア ファーマシューティカルズ インコーポレイテッド | 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体 |
| WO2006113552A2 (en) | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
| PT1891038E (pt) | 2005-05-13 | 2008-12-02 | Lilly Co Eli | N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio |
| JP2008546643A (ja) | 2005-06-06 | 2008-12-25 | スミスクライン ビーチャム コーポレーション | ４−置換アリールアミン誘導体および医薬組成物におけるその使用 |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| ES2339480T3 (es) * | 2005-06-24 | 2010-05-20 | Eli Lilly And Company | Derivados de tetrahidrocarbazol utiles como moduladores del receptor de androgenos (sarm). |
| WO2007005887A2 (en) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds, compositions and uses thereof |
| CA2617256C (en) | 2005-08-01 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤からなる強心薬 |
| US7776859B2 (en) | 2005-10-14 | 2010-08-17 | Bristol-Myers Squibb Company | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function |
| TW200730505A (en) | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
| HRP20130405T1 (en) | 2006-01-24 | 2013-07-31 | Janssen Pharmaceutica N.V. | 2-substituted benzimidazoles as selective androgen receptor modulators (sarms) |
| EP1991523B1 (en) | 2006-03-03 | 2012-08-15 | Orion Corporation | Selective androgen receptor modulators |
| MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
| MX2009000715A (es) | 2006-07-19 | 2009-07-22 | Osurf Ohio State University Re | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
| KR101202240B1 (ko) | 2006-08-24 | 2012-11-16 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
| WO2008042571A2 (en) | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
| WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
| UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
| EA017429B1 (ru) | 2007-08-07 | 2012-12-28 | Такеда Фармасьютикал Компани Лимитед | Циклические аминные соединения |
| EP2277124B1 (en) * | 2007-11-21 | 2016-11-09 | Medizinische Hochschule Hannover | Means for treating myosin-related diseases |
| AU2008339572B2 (en) | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2488990T3 (es) | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| SI2297100T1 (sl) | 2008-05-16 | 2013-02-28 | Eli Lilly & Company | Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja |
| WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
-
2011
- 2011-02-04 AU AU2011212813A patent/AU2011212813B2/en not_active Ceased
- 2011-02-04 JP JP2012552115A patent/JP5964756B2/ja not_active Expired - Fee Related
- 2011-02-04 US US13/576,754 patent/US8987319B2/en not_active Expired - Fee Related
- 2011-02-04 CA CA2788907A patent/CA2788907A1/en not_active Abandoned
- 2011-02-04 EP EP11740437.6A patent/EP2531029B1/en not_active Not-in-force
- 2011-02-04 BR BR112012019551A patent/BR112012019551A2/pt not_active IP Right Cessation
- 2011-02-04 WO PCT/US2011/023768 patent/WO2011097496A1/en not_active Ceased
- 2011-02-04 MX MX2012008995A patent/MX338831B/es active IP Right Grant
-
2015
- 2015-03-23 US US14/665,849 patent/US20150266821A1/en not_active Abandoned
-
2016
- 2016-02-26 JP JP2016035296A patent/JP2016138118A/ja active Pending
- 2016-11-07 US US15/330,845 patent/US20170121285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518902A5 (enExample) | ||
| JP5301469B2 (ja) | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 | |
| JP6469092B2 (ja) | イミダゾリジンジオン化合物及び薬物組成物 | |
| JP2019524883A5 (enExample) | ||
| JP2013537919A5 (enExample) | ||
| RU2008149242A (ru) | Малеатный сокристалл azd1152 | |
| AU2015341177B2 (en) | Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof | |
| RU2689315C2 (ru) | Соль гетероциклического соединения, замещенного галогеном | |
| JP2011514376A (ja) | 新規の１，２，４−トリアゾール誘導体およびそれらの製造方法 | |
| TWI761471B (zh) | Atf3誘導化合物 | |
| RU2013120556A (ru) | 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr | |
| BRPI0921097B1 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| TW202313592A (zh) | 喹啉胺類化合物、其製備方法及其在醫藥上的應用 | |
| CN103717594B (zh) | 包含二羟基取代基的trpv1拮抗剂及其用途 | |
| JP2017536362A5 (enExample) | ||
| HUE025111T2 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| CN1156454A (zh) | N-取代的3-氮杂双环[3，2，0]庚烷衍生物及其制备方法和应用 | |
| RU2543484C2 (ru) | Пиразины для использования в качестве модуляторов дельта-опиоидных рецепторов | |
| WO2001014382A1 (en) | Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan | |
| WO2006137527A1 (ja) | チアゾール誘導体 | |
| JP6618550B2 (ja) | 乳癌の予防又は治療用の化合物 | |
| CA2584757A1 (en) | Halogen substituted benzodiazepine derivatives | |
| CN1341021A (zh) | 多环噻唑体系用于制备预防或治疗肥胖的药物的用途 | |
| CA3071074A1 (en) | New propanamine derivatives for treating pain and pain related conditions | |
| JP2024169518A (ja) | 肥満に対する処置 |